

DiaSorin gets FDA clearance for PCT assay

June 2018—DiaSorin received clearance from the FDA to market the Liaison Brahms PCT II Gen assay for the quantitative determination of procalcitonin.

Procalcitonin can be used for the diagnosis of sepsis, severe sepsis, and septic shock, the differential diagnosis of clinically relevant bacterial infections and sepsis, and for evaluating the severity of a bacterial infection and systemic inflammatory reactions.

[DiaSorin](#), +39.0161.487.1